Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6P1M0
UPID:
S27A4_HUMAN
Alternative names:
Arachidonate--CoA ligase; Long-chain-fatty-acid--CoA ligase; Solute carrier family 27 member 4; Very long-chain acyl-CoA synthetase 4
Alternative UPACC:
Q6P1M0; A8K2F7; O95186; Q96G53
Background:
Long-chain fatty acid transport protein 4, also known as Solute carrier family 27 member 4, plays a crucial role in mediating the levels of long-chain fatty acids (LCFA) in cells. It facilitates their transport across cell membranes and functions as an acyl-CoA ligase, catalyzing the ATP-dependent formation of fatty acyl-CoA. This protein is essential for the formation of the epidermal barrier and fat absorption during early embryogenesis.
Therapeutic significance:
The protein's involvement in Ichthyosis prematurity syndrome, a keratinization disorder, highlights its therapeutic significance. Understanding the role of Long-chain fatty acid transport protein 4 could open doors to potential therapeutic strategies for treating this condition and improving patient outcomes.